Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

is an important cause of bleeding in patients with cirrhosis associated with portal hypertension. Histologically, the condition is characterized by dilation of the mucosal and submucosal vessels ...

Forty-six patients, 32 males and 14 females with portal hypertension and cirrhosis, were evaluated. The mean age of these patients was 48 ± 12 years (mean ± SD). In 43.5% of cases, cirrhosis ...

Portal hypertension is a life-threatening complication of cirrhosis and results in the development of esophagogastric varices and/or portal hypertensive gastropathy and subsequent bleeding.

A higher risk of liver transplant and death was observed in Ocaliva-treated patients vs those who received placebo.

Over time, this causes cirrhosis—scarring and tissue damage ... Scarring due to primary biliary cholangitis can affect blood ...

15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b ...